Nanexa AB (NANEXA) AI Stock Analysis

• Market Cap: €277.41M
• Dividend Yield: N/A
• Average Volume (3M): 266.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.22
• Revenue Growth: -60.33%
• EPS Growth: 58.04%
• Country: SE
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.08
• Shares Outstanding: 156,907,750
• 10 Day Avg. Volume: 346,691
• 30 Day Avg. Volume: 266,979
• PEG Ratio: 0.14
• Price to Book (P/B): 4.13
• Price to Sales (P/S): 12.03
• P/FCF Ratio: -5.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: kr1.50 ▼(-10.18% Downside)

Nanexa AB's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. The technical analysis further supports a bearish outlook with oversold conditions. Valuation metrics are unattractive due to negative earnings and lack of dividends, reinforcing the need for strategic improvements.

Nanexa AB Business Overview & Revenue Model

Company Description

Nanexa AB (NANEXA) is a biotechnology company specializing in drug delivery systems, particularly in the development of its proprietary platform, NEX-20, designed to enhance the efficacy and safety of therapeutic compounds. The company operates primarily in the pharmaceutical sector, focusing on the formulation and delivery of biopharmaceuticals to improve patient outcomes. Nanexa's core products include advanced drug formulations that utilize its unique technology to optimize the release profiles of active pharmaceutical ingredients.

How the Company Makes Money

Nanexa AB generates revenue primarily through the development and commercialization of its drug delivery technologies. The company earns money by entering into partnerships and collaborations with pharmaceutical companies that seek to utilize its proprietary NEX-20 platform for their drug development programs. These partnerships often involve licensing agreements, research and development funding, and milestone payments upon achieving specific development goals. Additionally, Nanexa may receive royalties from the sales of products developed using its technology. The company's financial performance is also supported by government grants and investments aimed at fostering innovation in biotechnology.

Nanexa AB Financial Statement Overview

Summary

Nanexa AB faces significant financial challenges, with declining revenues, persistent losses, and cash flow difficulties. While the balance sheet shows manageable leverage, the negative profitability metrics and cash flow issues indicate a need for strategic improvements to achieve financial stability and growth.

Income Statement

Nanexa AB's income statement reveals significant challenges, with declining revenue growth and negative profit margins. The TTM data shows a revenue decline of 15.15%, and the company has consistently reported negative net profit margins, indicating ongoing profitability issues. Despite a relatively high gross profit margin, the negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, suggesting manageable leverage. However, the return on equity is negative, reflecting poor profitability relative to shareholder equity. The equity ratio is stable, indicating a solid asset base, but the company's financial health is undermined by persistent losses.

Cash Flow

Cash flow analysis indicates a challenging environment with negative operating cash flow and free cash flow. Although there is a slight improvement in free cash flow growth, the operating cash flow to net income ratio remains negative, highlighting cash generation issues. The free cash flow to net income ratio suggests some ability to cover net losses, but overall cash flow remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.53M	24.36M	29.33M	2.86M	2.37M	2.37M
Gross Profit	38.40M	46.69M	59.16M	3.40M	4.31M	20.86M
EBITDA	-17.08M	-18.99M	-70.79M	-53.86M	-32.92M	-16.28M
Net Income	-30.95M	-24.91M	-76.40M	-58.57M	-36.00M	-21.74M
Balance Sheet
Total Assets	126.55M	91.82M	132.26M	170.19M	165.00M	53.69M
Cash, Cash Equivalents and Short-Term Investments	40.26M	10.29M	65.17M	81.18M	105.66M	12.69M
Total Debt	21.57M	3.71M	4.03M	6.27M	3.83M	3.89M
Total Liabilities	36.63M	20.90M	36.43M	61.10M	13.70M	10.34M
Stockholders Equity	89.92M	70.92M	95.83M	109.10M	151.29M	43.35M
Cash Flow
Free Cash Flow	-54.98M	-54.55M	-76.91M	-43.29M	-50.92M	-37.63M
Operating Cash Flow	-28.07M	-26.43M	-42.66M	-7.87M	-25.13M	-16.83M
Investing Cash Flow	-26.91M	-28.12M	-34.25M	-35.42M	-25.79M	-20.80M
Financing Cash Flow	53.93M	-327.00K	60.89M	18.81M	143.89M	38.94M

Nanexa AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NANEXA, the sentiment is Negative. The current price of 1.67 is below the 20-day moving average (MA) of 1.77, below the 50-day MA of 1.98, and below the 200-day MA of 1.87, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 40.80 is Neutral, neither overbought nor oversold. The STOCH value of 39.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NANEXA.

Nanexa AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALZCUR	47 Neutral	kr226.96M	―	-90.66%	―	―	15.74%
KLAR	41 Neutral	kr125.45M	―	-3899.10%	―	1523.75%	20.82%
NANEXA	39 Underperform	€277.41M	-8.29	-48.65%	―	-60.33%	58.04%
ENZY	38 Underperform	kr459.98M	―	―	―	19.17%	24.53%